Renfeng Guo
Fondatore presso INFLARX N.V.
Patrimonio netto: 2 M $ in data 30/04/2024
Posizioni attive di Renfeng Guo
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INFLARX N.V. | Direttore/Membro del Consiglio | 01/12/2007 | - |
| Direttore Tecnico/Scientifico/R&S | 01/12/2007 | - | |
| Fondatore | 01/12/2007 | - |
Storia della carriera di Renfeng Guo
Precedenti posizioni note di Renfeng Guo
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| University of Michigan | Corporate Officer/Principal | 01/01/2001 | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Direttore/Membro del Consiglio | - | - |
| Direttore Tecnico/Scientifico/R&S | 11/12/2007 | - | |
| Fondatore | 25/11/2009 | - |
Formazione di Renfeng Guo
| Norman Bethune Medical University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Germania | 3 |
| Cina | 2 |
| Stati Uniti | 2 |
Posizioni
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INFLARX N.V. | Health Technology |
| Aziende private | 1 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
- Borsa valori
- Insiders
- Renfeng Guo
- Esperienza
